| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.16 | 0.01 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.02 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.02 |